BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioCryst projects $1B peak sales for ORLADEYO, eyes global expansion

BioCryst Pharmaceuticals showcased strong performance driven by ORLADEYO's success, with a clear path towards $1 billion in peak sales and global expansion.
While facing challenges such as delays in BCX10013's development and managing expenses, the company remains focused on maximizing product value and market opportunities.
Opportunities lie in expanding ORLADEYO's market presence, exploring international sales, and investing in R&D for future growth and innovation.

BioCryst projects strong revenue growth for ORLADEYO, faces regulatory hurdles

BioCryst Pharmaceuticals demonstrates strong performance and revenue growth potential for ORLADEYO, aiming to exceed $320 million guidance for the year.
Challenges include revenue impact from free drug complexities and regulatory delays, with opportunities in global market expansion and pediatric therapy development.
The company's focus on patient care, financial stability, and long-term sales outlook positions BioCryst for continued growth and success in the pharmaceutical market.

BioCryst Pharmaceuticals on track to hit $320M in ORLADEYO sales

BioCryst Pharmaceuticals is confident in reaching $320 million in ORLADEYO sales this year through patient growth. Q3 and Q4 revenue growth expected to be steady, with opportunities for expansion outside the U.S.

BioCryst's ORLADEYO excels in Q3, faces challenges and growth opportunities

BioCryst Pharmaceuticals continues to see strong performance with ORLADEYO revenue and patient growth.
The company faces challenges with co-payment assistance programs and competitive market dynamics.
Opportunities lie in market education, pediatric patient expansion, and maintaining a competitive edge.
Despite expected expense increases, BioCryst remains focused on value creation and long-term growth.

BioCryst reports robust earnings, eyes $1B peak revenue for ORLADEYO

BioCryst Pharmaceuticals showcased strong financial performance and positive long-term data for ORLADEYO, aiming for $1 billion in global peak revenue.
While facing challenges with patient retention and market access, the company emphasized its growing product portfolio and accelerated path to profitability.
Opportunities lie in achieving profitability by 2026, improving market access, and leveraging therapy efficacy to drive revenue growth and market expansion.

BioCryst Pharmaceuticals excels in Q1, eyes Japanese market expansion

BioCryst Pharmaceuticals delivered strong Q1 results driven by ORLADEYO sales, raising revenue guidance for 2024 and advancing pipeline programs.
While facing challenges in expenses and gross to net margins, the company's strategic focus on market expansion and pipeline development presents growth opportunities.
Overall, BioCryst Pharmaceuticals shows promise with a balanced patient mix, strong market research projections, and high strategic interest in its flagship product.

BioCryst's ORLADEYO excels, revenue guidance raised amidst operational achievements

BioCryst Pharmaceuticals showcased robust performance in Q2 driven by ORLADEYO, with strong revenue growth and operational achievements.
Despite challenges like product portfolio diversification and profitability targets, the company's strategic focus on ORLADEYO's market expansion and revenue guidance increase highlights growth potential.
Opportunities lie in further leveraging ORLADEYO's success, exploring new market segments, and enhancing market strategies to drive sustained growth and market leadership.

BioCryst Pharmaceuticals reports robust revenue growth and pipeline advancements

BioCryst Pharmaceuticals delivered strong financial results driven by ORLADEYO's performance, showcasing market acceptance and revenue growth.
The company's pipeline advancements and proactive management approach position them well for future growth and product portfolio expansion.
While facing challenges in sustaining momentum and managing competition, BioCryst Pharmaceuticals has opportunities to capitalize on market demand and optimize operational strategies for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday morning after BofA Securities downgraded the stock and Oppenheimer lowered its price target.  BofA Securities analyst Tazeen Ahmad downgraded BioCryst from a Buy rating to a Neutral rating and announced a.

Why BioCryst Pharmaceuticals Stock Is Falling

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has paused enrollment in clinical trials with BCX9930 as the Company investigates elevated serum creatinine levels seen in some patients. The Company will not enroll new patients in the REDEEM-1, REDEEM-2, or RENEW clinical trials during.

Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder

The company is pausing patient enrollment in three clinical studies.

Why BioCryst Pharmaceuticals Stock Is Crashing Today

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading significantly lower Friday after the company paused enrollment in clinical trials with BCX9930 while it investigates elevated serum creatinine levels seen in some patients. During the investigation, the company will not enroll.

Why BioCryst Pharmaceuticals Stock Is Plunging Today

RESEARCH TRIANGLE PARK, N.C., April 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has paused enrollment in clinical trials with BCX9930 while the company investigates elevated serum creatinine levels seen in some patients.

BioCryst Pauses Enrollment in BCX9930 Clinical Trials

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) announced new long-term efficacy and safety data from the APeX-2 trial evaluating Orladeyo (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE). The results showed sustained reductions in attack rates and improved.

BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates

— Analysis from APeX-2 showed 94 percent attack-free days across all patients who completed 96 weeks of treatment — — Analysis from APeX-2 showed 94 percent attack-free days across all patients who completed 96 weeks of treatment —

BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)

The biotech's immediate future doesn't look profitable.

Why BioCryst Pharmaceuticals Stock Slid Today

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2021 Results - Earnings Call Transcript

BioCryst (BCRX) delivered earnings and revenue surprises of -29.03% and 2.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates

— Q4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021 —

BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones

By StoryTrading BioCryst's (NASDAQ: BCRX) stock price hit 15-year highs since our article was published on Benzinga earlier this month, but with the oral prophylactic treatment provider's 2021 financial results due out this Wednesday, some traders may be wondering whether it's.

BioCryst Hit 15-Year Highs But What's In Store Tomorrow For Earnings?

By Ben Rabizadeh – Fundamentals well positioned with $1B peak sales forecast for Orladeyo and $300M influx of cash from royalty deals

Is BioCryst (BCRX) Ready to Breakout to New Highs on Recent Catalysts?

RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2021 financial results Wednesday, February 23, 2022.

BioCryst to Report Fourth Quarter 2021 Financial Results on February 23

RESEARCH TRIANGLE PARK, N.C., Feb. 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed North Carolina Secretary of Commerce, and accomplished pharmaceutical operations executive, Machelle Sanders, to its board of directors.

BioCryst Appoints Machelle Sanders to Board of Directors

Royalty Pharma and OMERS Capital Markets (OMERS) recently committed $350 million in non-dilutive funding for BioCryst. BioCryst generated $120 million from their flagship product Orladeyo in FY2021 and raised guidance to a minimum of $250 million for FY2022.

Updated Guidance And Royalty Pharma Financing Demolish Short Thesis For BioCryst Pharmaceuticals

In December I prioritized gaining exposure to BCRX in our Core Biotech portfolio due to management's impressive execution in both the clinic and commercially.

BioCryst Pharmaceuticals: Updates To Thesis, Clinical And Commercial Momentum Accelerating

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present three abstracts featuring new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held live in Phoenix, Arizona, and virtually, from February 25-28, 2022.

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting

Investors loved the drugmaker's update earlier this week.

Why BioCryst Pharmaceuticals Stock Is Skyrocketing This Week

BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

BioCryst (BCRX) Moves 27.9% Higher: Will This Strength Last?

BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.

BioCryst (BCRX) Stock Up on Q4 Orladeyo Preliminary Sales

The stock price of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) increased by 27.85% today. This is why it happened.

BioCryst Pharmaceuticals Stock (BCRX): Why The Price Surged Today

Investors are cheering for preliminary fourth-quarter Orladeyo sales and guidance for 2022.

Why BioCryst Pharmaceuticals Stock Is Jumping on Monday

RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-1 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria (PNH).

BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH

The introduction of ORLADEYO has been a runaway success, and this is likely to continue with new payors and subscribers getting on board and international sales just around the corner. With two pivotal trials for BCX9930 in preparation after a very successful P1 trial, the company has another potential blockbuster that can be useful in multiple diseases.

News for BioCryst Pharmaceuticals Stock (BCRX)